~50% Of women over 50 experience some degree of female-pattern androgenetic alopecia. Which means your friends are dealing with this too
AGA Androgenetic alopecia (post-menopausal pattern thinning) is a different condition from 30s hormonal telogen effluvium, and this distinction changes treatment
6 months Minimum time to assess minoxidil response. Results aren't visible until after consistent use. This is the imperfect clarity moment

What menopause actually does to your hair

Estrogen protects your hair. It lengthens the growth phase and dampens DHT's effects on scalp follicles. When estrogen drops in menopause, that protection vanishes. Androgen levels fall too, but they don't fall as fast as estrogen. So suddenly your scalp is getting relatively more androgen effect than before, and DHT is now unmasked.

DHT locks onto follicle receptors and starts miniaturization: the follicle shrinks, produces thinner, shorter hair, cycle after cycle, until eventually it may stop producing visible hair. This is androgenetic alopecia (AGA). It depends on genetics, but about 50% of women get some degree of it by age 50. Which is why the earlier you catch it, the more you can preserve.

Research Note

A 2011 S1 guideline by Blumeyer et al. in the Journal of the German Society of Dermatology (JDDG): the first European evidence-based guideline for female AGA. Confirmed that topical minoxidil is the only topical treatment with sufficient RCT evidence to support a recommendation. The guideline also noted that female AGA is frequently underdiagnosed and often misattributed to nutritional deficiency or thyroid disease, delaying effective treatment.

AGA vs the diffuse shedding from your 30s

They feel the same, but they're not. Telogen effluvium (TE) from your 30s is reactive: stress, hormonal shifts, or nutritional gaps trigger it. It sheds evenly everywhere and resolves in 6 to 12 months once the trigger's gone.

AGA is patterned and relentless. In women, it typically shows as thinning across the crown and top, with the front hairline holding strong (different from male-pattern baldness). The parting widens first, usually. Most women wait, thinking it'll resolve. AGA is progressive and doesn't resolve on its own.

Practical Tip

Photograph your parting from directly above in the same lighting conditions once a month for three to four months. Progressive widening of the parting. Even subtle. Is more informative than daily shed counts, which vary too much to be meaningful on their own.

What actually works

Minoxidil topical is the gold standard for female AGA. The 2% solution (applied once or twice daily) works. The 5% form used in men shows benefit in women too. It extends the growth phase and fattens the follicles. You'll see results at six months, maximum at 12. Stop using it, and improvement reverses within months. It's maintenance, not a cure. Ask your doctor or dermatologist what concentration is right.

Low-level laser therapy (LLLT) shows promise as an add-on but doesn't have the same solid evidence as minoxidil. PRP injections look interesting in small studies but need bigger trials before anyone should count on it.

Tier 1 — First-line evidence

Topical minoxidil

Studies support regular topical application. Consult your doctor or dermatologist regarding appropriate concentration and frequency for your situation.

Tier 2 — Adjunct evidence

Low-level laser therapy (LLLT)

Multiple small RCTs suggest benefit as an adjunct. Evidence is less consistent than for minoxidil, but it is non-invasive with a good safety profile when used as directed.

Tier 3 — Emerging evidence

PRP injections

Early studies suggest hair density improvements; consult a dermatologist or dermatologist to assess suitability and expected outcomes based on your specific case.

When to see a dermatologist or dermatologist

🩺

When to seek specialist input

See a dermatologist or consultant dermatologist if your hair loss is rapid, if it extends to areas beyond the crown and top scalp, if you have associated scalp symptoms (itching, scaling, pain), or if minoxidil has not produced improvement after 12 months of consistent use. Alopecia areata: an autoimmune condition. Can co-exist with AGA and requires different treatment.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

  1. Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology. 2011;9(Suppl 6):S1–S57. doi:10.1111/j.1610-0379.2011.07802.x
  2. Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 2015;90(4):529–543. doi:10.1590/abd1806-4841.20153370
  3. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15–24. PubMed
  4. Suchonwanit P, et al. Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 2019;13:2777–2786. PubMed